404 reports of this reaction
2.5% of all BLEOMYCIN SULFATE reports
#6 most reported adverse reaction
PULMONARY TOXICITY is the #6 most commonly reported adverse reaction for BLEOMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 404 FDA adverse event reports linking BLEOMYCIN SULFATE to PULMONARY TOXICITY. This represents approximately 2.5% of all 16,267 adverse event reports for this drug.
Patients taking BLEOMYCIN SULFATE who experience pulmonary toxicity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY TOXICITY is a less commonly reported adverse event for BLEOMYCIN SULFATE, but still significant enough to appear in the safety profile.
In addition to pulmonary toxicity, the following adverse reactions have been reported for BLEOMYCIN SULFATE:
The following drugs have also been linked to pulmonary toxicity in FDA adverse event reports:
PULMONARY TOXICITY has been reported as an adverse event in 404 FDA reports for BLEOMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY TOXICITY accounts for approximately 2.5% of all adverse event reports for BLEOMYCIN SULFATE, making it a notable side effect.
If you experience pulmonary toxicity while taking BLEOMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.